A recent study showed that sorafenib resistance in hepatocellular carcinoma cells may at least partly be related to p38α (MAPK14)-dependent MEK-ERK activation, but other downstream proteins, such as STAT3, also seem to be important [34, 35]. This evidence concerns the gene MAPK14 and hepatocellular carcinoma.